目的 研究榮心丸聯(lián)合鹽酸曲美他嗪片治療急性病毒性心肌炎的臨床療效。方法 選取2018年10月—2019年10月在天津市薊州區(qū)人民醫(yī)院治療的100例急性病毒性心肌炎患者作為研究對(duì)象，所有患者隨機(jī)分為對(duì)照組和治療組，每組各50例。對(duì)照組患者口服鹽酸曲美他嗪片，1片/次，3次/d。治療組在對(duì)照組治療的基礎(chǔ)上口服榮心丸，6丸/次，3次/d。兩組患者接受治療1個(gè)月。觀察兩組患者的臨床療效，并比較兩組患者的心功能指標(biāo)、心肌酶譜指標(biāo)、抗氧化指標(biāo)、血清炎性指標(biāo)水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為72.5%、94.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組左室舒張末內(nèi)徑（LVEED）、左室收縮末內(nèi)徑（LVESD）均明顯降低，左心射血分?jǐn)?shù)（LVEF）明顯升高（P<0.05），且治療組LVEED、LVESD明顯低于對(duì)照組，LVEF明顯高于對(duì)照組（P<0.05）。治療后，兩組患者肌酸激酶同工酶（CK-MB）、心肌肌鈣蛋白Ⅰ（cTnI）水平均顯著降低（P<0.05）；且治療后治療組CK-MB、cTnI水平均明顯低于對(duì)照組（P<0.05）。治療后，兩組血清SOD水平顯著升高，MDA水平顯著降低（P<0.05）；且治療組患者血清SOD水平明顯高于對(duì)照組，血清MDA水平明顯低于對(duì)照組（P<0.05）。治療后，兩組血清白細(xì)胞介素（IL）-6、腫瘤壞死因子（TNF）-α、超敏C反應(yīng)蛋白（hs-CRP）水平均顯著降低（P<0.05），且治療組患者的血清炎性因子水平明顯低于對(duì)照組（P<0.05）。結(jié)論 榮心丸聯(lián)合鹽酸曲美他嗪片治療急性病毒性心肌炎具有較好的臨床療效，能夠改善患者心功能，降低炎性因子水平，值得在臨床上推廣應(yīng)用。

Objective To study the efficacy of Rongxin Pills combined with Trimetazidine Hydrochloride Tablets in treatment of acute viral myocarditis. Methods Patients (100 cases) with acute viral myocarditis in People's Hospital of Jizhou District of Tianjin from October 2018 to October 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 1 tablet/time, three daily. Patients in the treatment group were po administered with Rongxin Pills on the basis of the control group, 6 pills/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and cardiac function index, myocardial enzyme spectrum index, antioxidant index, and serum level of inflammatory index in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 72.5% and 94.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the values of left ventricular end diastolic diameter (LVEED) and left ventricular end systolic diameter (LVESD) in the two groups were significantly reduced, while the values of left ventricular ejection fraction (LVEF) were significantly increased (P<0.05), but the values of LVEED and LVESD in the treatment group were significantly lower than those in the control group, but the values of LVEF in the treatment group were significantly higher than that in the control group (P<0.05). After treatment, the levels of creatine kinase isoenzyme (CK-MB) and cardiac troponin I (cTnI) in the two groups were significantly decreased (P<0.05). After treatment, the levels of CK-MB and cTnI in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum level of SOD in the two groups were significantly increased, but the serum level of MDA was significantly decreased (P<0.05). The serum level of SOD in the treatment group was significantly higher than that of the control group, but the serum level of MDA in the treatment was significantly lower than that of the control group (P<0.05). After treatment, the serum levels of interleukin (IL)-6, tumor necrosis factor (TNF)-α, and high sensitivity C reactive protein (hs-CRP) in the two groups were significantly lower (P<0.05), and the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Rongxin Pills combined with Trimetazidine Hydrochloride Tablets has clinical curative effect in treatment of acute viral myocarditis, can improve the heart function of patients and reduce the level of inflammatory factors, which is worthy of clinical application.

R972